ACR 2017

The American College of Rheumatology's Annual Meeting is the world's premier rheumatology meeting. With more than 450 educational sessions, the meeting provides opportunities for professional development and access to the latest rheumatology research and clinical applications. Sign up for our daily email blasts on our registration page, and check back here during the conference for the full coverage.


FDA officials discuss safety data and drug approvals at the American College of Rheumatology Annual Meeting.
A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.
With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.
Patients with osteoarthritis may be able to receive targeted therapy based on phenotypes.
Major adverse cardiovascular event rates for baricitinib stabilize over time.
Methotrexate discontinuation was not observed to impact rheumatoid arthritis treatment with tocilizumab, according to an abstract presented at the 2017 American College of Rheumatology Annual Meeting.
Some patients with rheumatoid arthritis require a refined treat-to-target plan.
Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.